Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alterations in lipids after initiation of highly effective modulators in people with cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 1 Nov 2023

Despotes Katherine A, Ceppe Agathe S, Donaldson Scott H

Abstract excerpt

Risk of cardiovascular disease (CVD) may be changing in people with cystic fibrosis (pwCF) with widespread use of highly effective modulator therapy (HEMT). We performed a retrospective analysis of patients who had lipids checked before and after initiation of ivacaftor or elexacaftor/tezacaftor/ivacaftor. We hypothesized that HEMT negatively impacts lipids (total cholesterol [TC], low-density lipoprotein [LDL],...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Benzodioxoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cardiovascular Diseases

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Lipoproteins, LDL

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 37838486
DOI: 10.1016/j.jcf.2023.10.002
PMCID: PMC10803062

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alterations in lipids after initiation of highly effective modulators in people with cystic fibrosis.PMID 37838486Read ↗

Real world study on elexacaftor-tezacaftor-ivacaftor impact on cholesterol levels in adults with cystic fibrosis.Semantic proximity Read ↗

Impact of elexacaftor/tezacaftor/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index.Semantic proximity Read ↗

Clinical change 2 years from start of elexacaftor-tezacaftor-ivacaftor in severe cystic fibrosis.Semantic proximity Read ↗

Cystic fibrosis liver disease in the post-modulator era.Semantic proximity Read ↗

The effect of highly effective modulator therapy on systemic inflammation in cystic fibrosisSemantic proximity Read ↗

Trials and tribulations of highly effective modulator therapies in cystic fibrosis.Semantic proximity Read ↗

Update on Clinical Outcomes of Highly Effective Modulator Therapy.Semantic proximity Read ↗

The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis.Semantic proximity Read ↗

Impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in children with cystic fibrosis.Semantic proximity Read ↗

A survey assessing the impact of COVID-19 and elexacaftor/tezacaftor/ifavacaftor on both physical and mental health in adults with cystic fibrosis.Semantic proximity Read ↗

Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case series.Semantic proximity Read ↗

Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del/CFTR variant genotype after elexacaftor/tezacaftor/ivacaftor treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.